New molecular-targeted agents for colorectal cancer - Regorafenib and aflibercept

Shunsuke Kato

Research output: Contribution to journalShort surveypeer-review


Since the approval of bevacizumab, cetuximab, and panitumumab, development of novel molecular-targeted agents for colorectal cancer has been awaited. Recent phase III trials revealed that new molecular-target agents, regorafenib and aflibercept, are useful for previously treated mCRC. Regorafenib is an oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Aflibercept is a recombinant fusion protein that consists of vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, fused to the Fc portion of the human lgGI immunoglobulin. They are different in structure, but an anti-angiogenic effect is one of the main mechanisms of action they have in common. Consistent with the 18147 ML study, bevacizumab beyond progression (BBP), anti-angiogenic therapies are important in any line of chemotherapy for colorectal cancer.

Original languageEnglish
Pages (from-to)6-9
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Issue number1
Publication statusPublished - 2013 Jan 1


  • Aflibercept
  • Angiogenesis
  • Colorectal cancer
  • Regorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'New molecular-targeted agents for colorectal cancer - Regorafenib and aflibercept'. Together they form a unique fingerprint.

Cite this